Abstract
Thirteen patients were entered into an uncontrolled pilot study to investigate the response to, and toxicity of, a combination of cisplatinum (20 mg/m2) and bleomycin (6 mg/m2) infused daily for 5 days and repeated every 21 days up to a maximum of 4 cycles, in the treatment of squamous cell carcinoma of the bronchus. This regimen was subsequently followed by a split course of local irradiation. All patients have been followed to death. Six patients showed a partial response to chemotherapy while 7 showed no response or progressive disease. The median survival was 5 months. The median survival of the responders was 15 months and that of the nonresponders 3 months. Two patients developed the syndrome of inappropriate antidiuretic hormone secretion from which one died. The longest survivor, who died 26 months after the commencement of chemotherapy, had severe mediastinal and pulmonary fibrosis.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aisner J., Hansen H. H. Commentary: current status of chemotherapy for non-small cell lung cancer. Cancer Treat Rep. 1981 Nov-Dec;65(11-12):979–986. [PubMed] [Google Scholar]
- Bakowski M. T., Crouch J. C. Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat Rev. 1983 Sep;10(3):159–172. doi: 10.1016/0305-7372(83)90030-0. [DOI] [PubMed] [Google Scholar]
- Gralla R. J., Casper E. S., Kelsen D. P., Braun D. W., Jr, Dukeman M. E., Martini N., Young C. W., Golbey R. B. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med. 1981 Oct;95(4):414–420. doi: 10.7326/0003-4819-95-4-414. [DOI] [PubMed] [Google Scholar]
- Israël L., Aguilera J., Breau J. L. Traitement des cancers épidermoïdes par bléomycine et platine en administration continue prolongée. Série préliminaire de 80 cas avec 75% de réponses objectives. Nouv Presse Med. 1981 May 16;10(22):1817-8, 1823-4. [PubMed] [Google Scholar]
- Itri L. M., Gralla R. J., Kelsen D. P., Chapman R. A., Casper E. S., Braun D. W., Jr, Howard J. E., Golbey R., Heelan R. T. Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer. Cancer. 1983 Mar 15;51(6):1050–1055. doi: 10.1002/1097-0142(19830315)51:6<1050::aid-cncr2820510613>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
- Kjaer M. Radiotherapy of squamous, adeno- and large cell carcinoma of the lung. Cancer Treat Rev. 1982 Mar;9(1):1–20. doi: 10.1016/s0305-7372(82)80002-9. [DOI] [PubMed] [Google Scholar]
- Levin L., Sealy R., Barron J. Syndrome of inappropriate antidiuretic hormone secretion following dis-dichlorodiammineplatinum II in a patient with malignant thymoma. Cancer. 1982 Dec 1;50(11):2279–2282. doi: 10.1002/1097-0142(19821201)50:11<2279::aid-cncr2820501109>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
- Littlewood T. J., Smith A. P. Syndrome of inappropriate antidiuretic hormone secretion due to treatment of lung cancer with cisplatin. Thorax. 1984 Aug;39(8):636–637. doi: 10.1136/thx.39.8.636. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Odell W. D., Wolfsen A. R. Humoral syndromes associated with cancer. Annu Rev Med. 1978;29:379–406. doi: 10.1146/annurev.me.29.020178.002115. [DOI] [PubMed] [Google Scholar]
- Souhami R. L. The chemotherapy of lung cancer. Practitioner. 1983 Oct;227(1384):1553–1562. [PubMed] [Google Scholar]